Skip to content

Odor cue exposure therapy in alcohol use disorder

The Olfactory Systems Role in Evoking and Relieving Craving Associated Physiological Symptoms and Neural Reward Response in Alcohol Use and Comorbid Mood and Anxiety Disorders - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/06/089858
Enrollment
150
Registered
2025-06-30
Start date
Unknown
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F102- Alcohol dependence Health Condition 2: H- Substance Abuse Treatment

Interventions

Intervention1: Odor simulated virtual reality: A sub-cohort from Study 1 will undergo a randomized trial using virtual reality (VR) therapy with pleasant odor exposure for two weeks. A systematic odor

Sponsors

National Brain Research Center
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: To be eligible to participate in this study, an individual must meet all the following criteria: 1.Individuals between 18 to 65 years of age. 2.Individuals with a diagnosis of AUD (for the AUD cohort) OR without a diagnosis of AUD (for the healthy volunteer cohort). 3. Able to provide their own consent.

Exclusion criteria

Exclusion criteria: An individual who meets any of the following criteria will be excluded from participation in this study: 1. Currently have an uncontrolled medical disorder (i.e., gastrointestinal, endocrine, cardiac, psychiatric). 2. Any history of chronic rhinitis, eating disorder (including binge eating), acute or chronic upper respiratory infection, allergic rhinitis, nasal polyps, or daily use of nasal sprays. 3. Altered cranial nerves associated with taste and olfaction identified by neurological evaluation during physical exam. 4. Positive pregnancy test, currently pregnant or breastfeeding. 5. Hypoglycemic drug intake. 6. Current cold/flu symptoms or temporary loss of smell 7. Persistent loss of smell due to COVID-19.

Design outcomes

Primary

MeasureTime frame
olfactory scores, cognition, craving and physiological responsesTimepoint: Pretherapy, Post 1 week therapy, Post 2 week therapy and Post 3 week therapy.

Secondary

MeasureTime frame
Neural outcomes including brain activity on odor cue task, brain connectivity patterns, metabolic profiles in brain regions specific to reward, structural brain regions.Timepoint: Pretherapy, Post 1 week therapy, Post 2 week therapy & Post 3 week therapy.

Countries

India

Contacts

Public ContactDr Khushbu Agarwal

National Brain Research Centre

khushbu.agarwal@nbrc.ac.in9968845495

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026